Boehringer Ingelheim appoints new CMO

11 September 2018

Boehringer Ingelheim today announced that Dr Christopher Corsico, senior vice president, corporate division Medicine and chief medical officer, will be leaving the German family-owned pharma major to pursue his career outside of the company effective December 31, 2018.

Dr Thor Voigt, currently medical director Germany, has agreed to assume the leadership of the Medicine unit and to become CMO, effective October 1, 2018.

Allan Hillgrove, a member of the board of managing directors with responsibility for the Human Pharma Business unit said: "We are grateful to Dr Corsico for his valuable contributions during many years of service for Boehringer Ingelheim. He has been instrumental for Boehringer Ingelheim’s drive for medical and patient focus. On behalf of the Board of Managing Directors I wish him all the best for the future."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK